Integrating patient perspectives into personalized medicine in idiopathic pulmonary fibrosis

Frontiers in Medicine

Volumn 4, Issue DEC, 2017, Pages

  Moor, Catharina C ^a   Heukels, Peter ^a   Kool, Mirjam ^a   Wijsenbeek, Marlies S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Health related quality of life; Idiopathic pulmonary fibrosis; Patient experiences; Patient reported outcomes; Personalized medicine; Personomics

Indexed keywords

EID: 85050757426     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2017.00226     Document Type: Short Survey

References (96)

1. Potter P. Hippocrates Vol VI. Diseases, Internal Affections. Cambridge, MA, London: Harvard University Press, William Heinemann LTD (1988)
2. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med (2002) 165(2):277-304. doi:10.1164/ajrccm.165.2.ats01
3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 183(6):788-824. doi:10.1164/rccm.2009-040GL
4. The Voice of the Patient: A Series of Reports from the U.S. Food and Drug Administration's (FDA's) Patient-Focused Drug Development Initiative. Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) (2015)
5. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 370(22):2071-82. doi:10.1056/NEJMoa1402584
6. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med (2014) 370(22):2083-92. doi:10.1056/NEJMoa1402582
7. Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med (2015) 21(5):470-8. doi:10.1097/MCP.0000000000000187
8. Macagno F, Varone F, Leone PM, Mari PV, Panico L, Berardini L, et al. New treatment directions for IPF: current status of ongoing and upcoming clinical trials. Expert Rev Respir Med (2017) 11(7):533-48. doi:10.1080/17476348.2017.1335601
9. Di Paolo A, Sarkozy F, Ryll B, Siebert U. Personalized medicine in Europe: not yet personal enough? BMC Health Serv Res (2017) 17(1):289. doi:10.1186/s12913-017-2205-4
10. Clarke DL, Murray LA, Crestani B, Sleeman MA. Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis? Pharmacol Ther (2017) 169:35-46. doi:10.1016/j.pharmthera.2016.09.010
11. Spagnolo P, Cottin V. Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. J Med Genet (2017) 54(2):93-9. doi:10.1136/jmedgenet-2016-103973
12. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 183(4):431-40. doi:10.1164/rccm.201006-0894CI
13. Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med (1995) 41(10):1383-94. doi:10.1016/0277-9536(95)00116-O
14. Swigris JJ, Stewart AL, Gould MK, Wilson SR. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes (2005) 3:61. doi:10.1186/1477-7525-3-61
15. Duck A, Spencer LG, Bailey S, Leonard C, Ormes J, Caress AL. Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs (2015) 71(5):1055-65. doi:10.1111/jan.12587
16. Overgaard D, Kaldan G, Marsaa K, Nielsen TL, Shaker SB, Egerod I. The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J (2016) 47(5):1472-80. doi:10.1183/13993003.01566-2015
17. Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm Med (2016) 16:10. doi:10.1186/s12890-016-0171-y
18. Yount SE, Beaumont JL, Chen SY, Kaiser K, Wortman K, Van Brunt DL, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung (2016) 194(2):227-34. doi:10.1007/s00408-016-9850-y
19. Wijsenbeek M, van Manen M, Bonella F. New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises? Curr Opin Pulm Med (2016) 22(5):434-41. doi:10.1097/MCP.0000000000000294
20. Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 12:124. doi:10.1186/s12955-014-0124-1
21. Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax (2012) 67(9):804-10. doi:10.1136/thoraxjnl-2012-201581
22. Britten N, Pope C, Halford S, Richeldi L. What if we made stratified medicine work for patients? Lancet Respir Med (2016) 4(1):8-10. doi:10.1016/S2213-2600(15)00499-3
23. Ziegelstein RC. Personomics. JAMA Intern Med (2015) 175(6):888-9. doi:10.1001/jamainternmed.2015.0861
24. MRC. (2017). Available from: https://www.mrc.ac.uk/research/initiatives/stratified-medicine/
25. Brownell R, Kaminski N, Woodruff PG, Bradford WZ, Richeldi L, Martinez FJ, et al. Precision medicine: the new frontier in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2016) 193(11):1213-8. doi:10.1164/rccm.201601-0169CI
26. Sykiotis GP, Kalliolias GD, Papavassiliou AG. Pharmacogenetic principles in the Hippocratic writings. J Clin Pharmacol (2005) 45(11):1218-20. doi:10.1177/0091270005281091
27. Daccord C, Maher TM. Recent advances in understanding idiopathic pulmonary fibrosis. F1000Res (2016) 5:F1000 Faculty Rev-1046. doi:10.12688/f1000research.8209.1
28. Dietel M. Molecular pathology: a requirement for precision medicine in cancer. Oncol Res Treat (2016) 39(12):804-10. doi:10.1159/000453085
29. Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer (2016) 16(8):525-37. doi:10.1038/nrc.2016.56
30. Hoyne GF, Elliott H, Mutsaers SE, Prele CM. Idiopathic pulmonary fibrosis and a role for autoimmunity. Immunol Cell Biol (2017) 95(7):577-83. doi:10.1038/icb.2017.22
31. Maher TM. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Curr Opin Pulm Med (2013) 19(5):460-5. doi:10.1097/MCP.0b013e328363f4b7
32. Hambly N, Shimbori C, Kolb M. Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers. Respirology (2015) 20(7):1010-22. doi:10.1111/resp.12569
33. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2014) 307(9):L681-91. doi:10.1152/ajplung.00014.2014
34. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 45(6):613-20. doi:10.1038/ng.2609
35. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 364(16):1503-12. doi:10.1056/NEJMoa1013660
36. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 309(21):2232-9. doi:10.1001/jama.2013.5827
37. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med (2013) 1(4):309-17. doi:10.1016/S2213-2600(13)70045-6
38. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2015) 192(12):1475-82. doi:10.1164/rccm.201505-1010OC
39. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 190(8):906-13. doi:10.1164/rccm.201403-0541OC
40. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med (2014) 2(7):548-56. doi:10.1016/S2213-2600(14)70069-4
41. Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji W, Cookson WO, et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res (2017) 18(1):29. doi:10.1186/s12931-017-0511-3
42. Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, et al. Host-microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2017) 195(12):1640-50. doi:10.1164/rccm.201607-1408OC
43. Huang Y, Ma SF, Espindola MS, Vij R, Oldham JM, Huffnagle GB, et al. Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2017) 196(2):208-19. doi:10.1164/rccm.201607-1525OC
44. ClinicalTrials.gov. CleanUP IPF for the Pulmonary Trials Cooperative (CleanUp-IPF), NCT02759120. (2017). Available from: https://clinicaltrials.gov/ct2/show/NCT02759120
45. Russell AM, Swigris JJ. What's it like to live with idiopathic pulmonary fibrosis? Ask the experts. Eur Respir J (2016) 47(5):1324-6. doi:10.1183/13993003.00109-2016
46. Sampson C, Gill BH, Harrison NK, Nelson A, Byrne A. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med (2015) 15:155. doi:10.1186/s12890-015-0145-5
47. van Manen MJG, Kreuter M, van den Blink B, Oltmanns U, Palmowski K, Brunnemer E, et al. What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. ERJ Open Res (2017) 3(1):00065-2016. doi:10.1183/23120541.00065-2016
48. Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, et al. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J (2016) 47(2):597-606. doi:10.1183/13993003.01204-2015
49. Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev (2015) 24(135):58-64. doi:10.1183/09059180.00011514
50. Koschel DCV, Skold M, Tomassetti S, Azuma A, Giot C, Yocum D, et al. Pirfenidone post-authorization safety registry (PASSPORT)-interim analysis of IPF treatment. Eur Respir J (2014) 44:1904
51. van Manen MJ, Geelhoed JJ, Tak NC, Wijsenbeek MS. Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Ther Adv Respir Dis (2017) 11(3):157-69. doi:10.1177/1753465816686743
52. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J (2015) 46(4):1113-30. doi:10.1183/13993003.02316-2014
53. Suzuki A, Kondoh Y. The clinical impact of major comorbidities on idiopathic pulmonary fibrosis. Respir Investig (2017) 55(2):94-103. doi:10.1016/j.resinv.2016.11.004
54. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One (2016) 11(3):e0151425. doi:10.1371/journal.pone.0151425
55. Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med (2015) 8:309-18. doi:10.2147/IJGM.S74880
56. Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med (2014) 108(4):647-53. doi:10.1016/j.rmed.2014.01.008
57. Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ (2012) 15(5):829-35. doi:10.3111/13696998.2012.680553
58. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res (2017) 18(1):139. doi:10.1186/s12931-017-0621-y
59. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf (2014) 13(1):57-65. doi:10.1517/14740338.2013.827660
60. Jo HE, Randhawa S, Corte TJ, Moodley Y. Idiopathic pulmonary fibrosis and the elderly: diagnosis and management considerations. Drugs Aging (2016) 33(5):321-34. doi:10.1007/s40266-016-0366-1
61. Guidance for Industry. Patient-Reported Outocome Measures: Use in Medical Product Development to Support Labeling Claims. US Department of Health and Human Services, Food and Drug Administration (2009). Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf
62. Black N. Patient reported outcome measures could help transform healthcare. BMJ (2013) 346:f167. doi:10.1136/bmj.f167
63. Brooks R. EuroQol: the current state of play. Health Policy (1996) 37(1):53-72. doi:10.1016/0168-8510(96)00822-6
64. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 30(6):473-83. doi:10.1097/00005650-199206000-00002
65. Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med (1991) 85(Suppl B):25-31; discussion 33-7. doi:10.1016/S0954-6111(06)80166-6
66. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2010) 104(2):296-304. doi:10.1016/j.rmed.2009.09.006
67. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's respiratory questionnaire. Thorax (2010) 65(10):921-6. doi:10.1136/thx.2010.139121
68. Matsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, et al. COPD assessment test for measurement of health status in patients with idiopathic pulmonary fibrosis: a cross-sectional study. Respirology (2017) 22(4):721-7. doi:10.1111/resp.12936
69. Sinha APAS, Birring SS. The King's Brief Interstitial Lung Disease (K-BILD) questionnaire; an updated minimal important difference. Eur Respir J (2016) 48(Suppl 60):PA808. doi:10.1183/13993003.congress-2016.PA808
70. Graney B, Johnson N, Evans CJ, Ryan A, Matsui A, Raimundo K, et al. Living with idiopathic pulmonary fibrosis (L-IPF): developing a patient-reported symptom and impact questionnaire to assess health-related quality of life in IPF. Am J Respir Crit Care Med (2017) 195:A5353
71. Russell AM, Doyle AM, Fleming S, Burdett C, Ross D, Aden Z, et al. Development of a patient reported outcome measure (PROM) in idiopathic pulmonary fibrosis (IPF): incorporating a research partnership with patients. Am J Respir Crit Care Med (2015) 191:A5190
72. Kimman ML, Rotteveel AH, Wijsenbeek M, Mostard R, Tak NC, van Jaarsveld X, et al. Development and pretesting of a questionnaire to assess patient experiences and satisfaction with medications (PESaM questionnaire). Patient (2017) 10(5):629-42. doi:10.1007/s40271-017-0234-z
73. Russell AM, Sonecha S, Datta A, Hewitt R, Howell I, Elliott A, Wickremasinghe M. Development of patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF). Thorax (2016) 71:A238. doi:10.1136/thoraxjnl-2016-209333.419
74. Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 106(10):1447-55. doi:10.1016/j.rmed.2012.06.018
75. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J (2010) 36(5):1067-72. doi:10.1183/09031936.00152609
76. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD (2005) 2(1):99-103. doi:10.1081/COPD-200050666
77. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc (1982) 14(5):377-81. doi:10.1249/00005768-198205000-00012
78. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 189(3):250-5. doi:10.1164/rccm.201310-1863PP
79. Matsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, et al. Depression is significantly associated with the health status in patients with idiopathic pulmonary fibrosis. Intern Med (2017) 56(13):1637-44. doi:10.2169/internalmedicine.56.7019
80. Lechtzin N, Hilliard ME, Horton MR. Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis. Chest (2013) 143(6):1745-9. doi:10.1378/chest.12-2870
81. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax (2003) 58(4):339-43. doi:10.1136/thorax.58.4.339
82. Raj AA, Pavord DI, Birring SS. Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire? Handb Exp Pharmacol (2009) 187:311-20. doi:10.1007/978-3-540-79842-2_16
83. Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective cough frequency in idiopathic pulmonary fibrosis. Cough (2010) 6:4. doi:10.1186/1745-9974-6-4
84. Kotecha J, Atkins C, Wilson A. Patient confidence and quality of life in idiopathic pulmonary fibrosis and sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2016) 33(4):341-8
85. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE Jr, Koch GG, et al. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J (2015) 46(1):243-9. doi:10.1183/09031936.00200614
86. Furukawa T, Taniguchi H, Ando M, Kondoh Y, Kataoka K, Nishiyama O, et al. The St. George's Respiratory Questionnaire as a prognostic factor in IPF. Respir Res (2017) 18(1):18. doi:10.1186/s12931-017-0503-3
87. Santana MJ, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. Qual Life Res (2014) 23(5):1505-13. doi:10.1007/s11136-013-0596-1
88. Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res (2013) 13:211. doi:10.1186/1472-6963-13-211
89. Koff PB, Jones RH, Cashman JM, Voelkel NF, Vandivier RW. Proactive integrated care improves quality of life in patients with COPD. Eur Respir J (2009) 33(5):1031-8. doi:10.1183/09031936.00063108
90. Rasmussen LM, Phanareth K, Nolte H, Backer V. Internet-based monitoring of asthma: a long-term, randomized clinical study of 300 asthmatic subjects. J Allergy Clin Immunol (2005) 115(6):1137-42. doi:10.1016/j.jaci.2005.03.030
91. Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst (2017) 109:9. doi:10.1093/jnci/djx029
92. World Health Organization. eHealth. (2017). Available from: http://www.who.int/ehealth/en/
93. Wicks P, Stamford J, Grootenhuis MA, Haverman L, Ahmed S. Innovations in e-health. Qual Life Res (2014) 23(1):195-203. doi:10.1007/s11136-013-0458-x
94. Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2016) 194(8):989-97. doi:10.1164/rccm.201511-2152OC
95. Johannson KA, Vittinghoff E, Morisset J, Lee JS, Balmes JR, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J (2017) 50(1):1602406. doi:10.1183/13993003.02406-2016
96. Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, et al. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med (2017) 17(1):104. doi:10.1186/s12890-017-0444-0